Streetbeat News

SABSW

SAB Biotherapeutics, Inc.

http://www.sabbiotherapeutics.com

Industry

Biotechnology

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

Open

0.05

Mkt cap

471K

Volume

3.7K

High

0.05

P/E Ratio

0.17

52-wk high

0.05

Low

0.05

Div yield

N/A

52-wk low

0.05

Trading for SABSW was halted and then resumed at 9:00 AM ET, with updated quotation resumption times following the release of news.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 2:00 pm

Trading on the stock SABSW has been halted at 7:50:00 p.m. ET due to pending news. The halt is in place to manage market orderliness and ensure fair information dissemination.

Portfolio Pulse from Benzinga Newsdesk

January 05, 2024 | 12:50 am

SAB Biotherapeutics has announced its plans to file IND and CTA with the U.S. FDA and EMA in 2024 to progress its SAB-142 into a Phase 2b clinical study.

Portfolio Pulse from Benzinga Newsdesk

November 29, 2023 | 12:01 pm

SAB Biotherapeutics has secured financing led by RA Capital Management, with participation from BVF Partners, Sessa Capital, Commodore Capital, RTW Investments, Marshall Wace, and the JDRF T1D Fund.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:16 am

SAB Biotherapeutics has announced that it has received funding to support the clinical advancement of SAB-142, a potential disease-modifying treatment. The company did not disclose the amount of funding or the source.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:16 am

SAB Biotherapeutics has announced a private placement of up to $130 million to advance the development of its lead drug candidate for Type 1 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 11:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.